BR112014025469A2 - uso de bactérias probióticas no tratamento de infecções bacterianas e regeneração da pele, bem como composições compreendendo cepas das referidas bactérias - Google Patents

uso de bactérias probióticas no tratamento de infecções bacterianas e regeneração da pele, bem como composições compreendendo cepas das referidas bactérias

Info

Publication number
BR112014025469A2
BR112014025469A2 BR112014025469A BR112014025469A BR112014025469A2 BR 112014025469 A2 BR112014025469 A2 BR 112014025469A2 BR 112014025469 A BR112014025469 A BR 112014025469A BR 112014025469 A BR112014025469 A BR 112014025469A BR 112014025469 A2 BR112014025469 A2 BR 112014025469A2
Authority
BR
Brazil
Prior art keywords
bacteria
strains
treatment
well
compositions
Prior art date
Application number
BR112014025469A
Other languages
English (en)
Other versions
BR112014025469B1 (pt
Inventor
Mcbain Andrew
o'neill Catherine
Original Assignee
Skinbiotherapeutics Plc
Skinbiotix Ltd
Univ Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46209083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014025469(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Skinbiotherapeutics Plc, Skinbiotix Ltd, Univ Manchester filed Critical Skinbiotherapeutics Plc
Publication of BR112014025469A2 publication Critical patent/BR112014025469A2/pt
Publication of BR112014025469B1 publication Critical patent/BR112014025469B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/20—Bacteria; Substances produced thereby or obtained therefrom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/10—General cosmetic use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/70—Biological properties of the composition as a whole

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Birds (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

uso de bactérias probióticas no tratamento de infecções bacterianas e regeneração da pele, bem como composições compreendendo cepas das referidas bactérias. a presente invenção refere-se ao uso de bactérias probióticas e seus lisados, na fabricação de um medicamento para tratamento de infecções, incluindo infeccções cutâneas, bem como em processos de regeneração ou o reparo da barreira cutânea, em que a bactéria probiótica é uma cepa de lactobacillus rhamnosus, uma cepa de lactobacillus reuteri, ou uma cepa de bifidobacterium longum. a presente invenção refere-se a composições cosméticas, farmacêuticas e antibacterianas compreendendo cepas de bactérias probióticas.
BR112014025469-9A 2012-04-13 2013-03-15 Usos de lisado filtrado da bactéria probiótica lactobacillus rhamnosus gg atcc 53103 no reparo ou regeneração da barreira cutânea e no tratamento cosmético para aumentar a função de barreira cutânea BR112014025469B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1206599.1A GB201206599D0 (en) 2012-04-13 2012-04-13 Probiotic bacteria
GB1206599.1 2012-04-13
PCT/GB2013/050646 WO2013153358A1 (en) 2012-04-13 2013-03-15 Probiotic bacteria

Publications (2)

Publication Number Publication Date
BR112014025469A2 true BR112014025469A2 (pt) 2021-06-01
BR112014025469B1 BR112014025469B1 (pt) 2022-07-26

Family

ID=46209083

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014025469-9A BR112014025469B1 (pt) 2012-04-13 2013-03-15 Usos de lisado filtrado da bactéria probiótica lactobacillus rhamnosus gg atcc 53103 no reparo ou regeneração da barreira cutânea e no tratamento cosmético para aumentar a função de barreira cutânea

Country Status (13)

Country Link
US (2) US20150079040A1 (pt)
EP (2) EP3888628A1 (pt)
JP (2) JP6505594B2 (pt)
CN (1) CN104582712B (pt)
AU (1) AU2013246701B2 (pt)
BR (1) BR112014025469B1 (pt)
CA (1) CA2908812C (pt)
ES (1) ES2883926T3 (pt)
GB (1) GB201206599D0 (pt)
HK (1) HK1201208A1 (pt)
MX (1) MX362725B (pt)
RU (1) RU2656152C2 (pt)
WO (1) WO2013153358A1 (pt)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY197622A (en) 2010-12-31 2023-06-28 Abbott Lab Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
ES2804258T3 (es) 2010-12-31 2021-02-05 Abbott Lab Procedimientos para reducir la incidencia de estrés oxidativo usando oligosacáridos de leche humana, vitamina C y agentes antiinflamatorios
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
MX350782B (es) 2011-07-22 2017-09-18 Abbott Lab Galacto-oligosacaridos para prevenir lesion y/o promover cicatrizacion del tracto gastrointestinal.
MX368124B (es) 2011-08-29 2019-09-19 Abbott Lab Oligosacaridos de leche humana para prevenir lesion y/o promover cicatrizacion del tracto gastrointestinal.
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
GB201409541D0 (en) * 2014-05-29 2014-07-16 Univ Manchester Probiotic Bacteria
CA2967039A1 (en) * 2014-11-10 2016-05-19 National Institutes Of Health Probiotic therapeutic applications
ME03077B (me) 2014-12-23 2019-01-20 4D Pharma Res Ltd Pirinski polipepтid i imunska modulacija
SI3065748T1 (en) 2014-12-23 2018-05-31 4D Pharma Research Limited Severe bacteroid tethethioomycron and its use in reducing inflammation
EP3735979A1 (en) * 2014-12-23 2020-11-11 Ilya Pharma AB Methods for wound healing
WO2016124239A1 (en) 2015-02-04 2016-08-11 Aurealis Oy Recombinant probiotic bacteria for use in the treatment of a skin dysfunction
WO2016176380A1 (en) * 2015-04-28 2016-11-03 The Procter & Gamble Company Compositions comprising whole, non-viable micrococcus for improving skin health
EP3206700B1 (en) 2015-06-15 2019-06-05 4D Pharma Research Limited Compositions comprising bacterial strains
MA51639A (fr) 2015-06-15 2020-04-15 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
PE20180267A1 (es) 2015-06-15 2018-02-06 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
AU2016338321A1 (en) * 2015-10-15 2018-05-17 Natura Cosméticos S.A. Cosmetic composition having probiotic bacteria
GB2544481B (en) * 2015-11-16 2019-12-11 Century International Enterprises Ltd A wearable article and a method for producing a wearable article
LT3209310T (lt) 2015-11-20 2018-04-25 4D Pharma Research Limited Kompozicijos, apimančios bakterinius kamienus
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
CN105456178A (zh) * 2015-12-16 2016-04-06 刘春花 一种活性生物酶调理原液
BE1023416B1 (nl) 2016-02-26 2017-03-14 Chrisal Nv Synbiotisch preparaat
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
NZ745678A (en) 2016-03-04 2019-03-29 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
AU2017240069B2 (en) 2016-03-31 2024-03-07 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
WO2017173240A1 (en) 2016-03-31 2017-10-05 Gojo Industries, Inc. Antimicrobial peptide stimulating cleansing composition
US10293005B2 (en) 2016-04-19 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of gram negative species to treat atopic dermatitis
AU2017253935B2 (en) 2016-04-19 2021-07-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of gram negative species to treat atopic dermatitis
GB201608762D0 (en) 2016-05-18 2016-06-29 Skinbiotix Ltd Compositions and uses thereof
BE1024425B9 (nl) * 2016-06-21 2018-03-26 Yun NV Dermatologische preparaten voor het onderhouden en/of herstellen van een gezonde huidmicrobiota
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
WO2018051895A1 (ja) 2016-09-15 2018-03-22 キリン株式会社 乳酸菌を有効成分として含む、皮膚における特定細菌の異常増殖に起因する皮膚の状態の悪化を防止又は改善するための組成物
DK3538118T3 (da) * 2016-11-11 2021-05-25 Sjaellands Univ Dermatologisk Afdeling Levende saprofytbakterier til anvendelse til behandling af hidradenitis suppurativa
CA3043748A1 (en) 2016-11-23 2018-05-31 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
JP7130220B2 (ja) * 2016-12-28 2022-09-05 高梨乳業株式会社 皮膚保湿剤
JP2018104387A (ja) * 2016-12-28 2018-07-05 高梨乳業株式会社 皮膚動脈交感神経抑制剤
JP2020520911A (ja) 2017-05-22 2020-07-16 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 細菌株を含む組成物
TW201907931A (zh) 2017-05-24 2019-03-01 英商4D製藥研究有限公司 包含細菌菌株之組合物
TW201919670A (zh) 2017-06-14 2019-06-01 英商4D製藥研究有限公司 包含細菌品系之組成物
PL3804737T3 (pl) 2017-06-14 2022-09-12 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
RU2748594C2 (ru) * 2017-12-21 2021-05-27 Общество С Ограниченной Ответственностью "Сплат Глобал" Композиция на основе бромелаина и лизата бактерий для профилактики заболеваний полости рта
CN108125902A (zh) * 2018-01-08 2018-06-08 北京科拓恒通生物技术股份有限公司 一种益生菌组合物、护肤精华液和面膜及其制备方法
CN112105370A (zh) * 2018-02-24 2020-12-18 皮肤清洁有限公司 用于治疗皮肤病的组合物、设备、系统、试剂盒和方法
WO2019197672A1 (fr) 2018-04-13 2019-10-17 Danstar Ferment Ag Utilisation de bactéries probiotiques à titre d'actif procurant un effet tenseur cutané
BR112020021204A2 (pt) * 2018-04-18 2021-01-19 Danstar Ferment Ag Composição, método para aliviar ou suprimir os sintomas, método de formulação de uma composição para aliviar ou suprimir os sintomas, uso de uma composição e uso não terapêutico de pelo menos uma cepa bacteriana
GB201807576D0 (en) 2018-05-09 2018-06-20 Skinbiotherapeutics Plc Compositions and uses thereof
SG11202011188SA (en) 2018-05-11 2020-12-30 Forte Subsidiary Inc Compositions for the treatment of skin conditions
WO2020001747A1 (en) 2018-06-26 2020-01-02 Symrise Ag Lactobacillus plantarum for skin care
EP3817726A1 (en) * 2018-07-04 2021-05-12 Chr. Hansen A/S Topical compositions comprising viable probiotic bacteria
SG11202100709XA (en) * 2018-07-23 2021-02-25 The United States Of America As Represented By The Secretary Use of gram negative species to treat atopic dermatitis
ES2928223T3 (es) * 2018-07-24 2022-11-16 Biogaia Ab Selección y uso de bacterias de apoyo a la melatonina para reducir los cólicos infantiles
EP3827102A1 (en) * 2018-07-24 2021-06-02 Biogaia AB Therapeutic methods using bacterial strains which are capable of increasing adenosine levels
KR102091175B1 (ko) * 2018-09-05 2020-04-23 서울대학교산학협력단 장내 항염증 및 균총 개선 활성을 갖는 락토바실러스 람노서스 균주
JP7219033B2 (ja) * 2018-09-14 2023-02-07 ポーラ化成工業株式会社 Ｍ．ａｅｒｉｌａｔａを有効成分とする皮膚外用組成物
FR3090383B1 (fr) * 2018-12-21 2021-05-28 Lvmh Rech Composition comprenant un extrait de Lactobacillus rhamnosus
KR20210118836A (ko) 2018-12-21 2021-10-01 매트리시스 바이오사이언스, 인크. 미생물 유래된 물질의 전달을 위한 국소 제형
KR102123022B1 (ko) * 2018-12-31 2020-06-16 코스맥스 주식회사 피부에 효능이 있는 고농도 프로바이오틱스를 포함하는 조성물
CN109517765A (zh) * 2019-01-11 2019-03-26 谭瑛 一种粪链球菌及其应用
EP3911345A4 (en) 2019-01-15 2022-10-26 Novozymes A/S SPORE-BASED PROBIOTIC COMPOSITION FOR MODULATION OF DERMAL AND SUBDERMAL PROPERTIES
IT201900000801A1 (it) * 2019-01-18 2020-07-18 Proge Farm Srl Composizione comprendente batteri probiotici non vitali e suo uso in terapia
CL2019000845A1 (es) * 2019-03-29 2019-08-30 Monje Marcela Maritza Espinoza Formulación probiótica que comprende cepas weissella viridescens aisladas desde helix aspersa müller y su uso para la prevención y tratamiento coadyuvante del acné vulgar
KR20200130174A (ko) * 2019-05-08 2020-11-18 김연란 미생물 유래 핵산 및 이의 용도
WO2020256110A1 (ja) * 2019-06-21 2020-12-24 国立大学法人京都大学 タイトジャンクション形成誘導剤
CN112438995A (zh) 2019-09-04 2021-03-05 台达电子工业股份有限公司 抑制具万古霉素抗药性肠球菌的益生菌及其组合与其用途
CN110393772A (zh) * 2019-09-05 2019-11-01 尹洪莉 一种促进放疗患者皮肤伤口愈合的药物组合物及制备方法
DE102019007507A1 (de) * 2019-10-28 2021-04-29 Beiersdorf Ag Zusammensetzung mit probiotischen Bakterien und Protektor-Stämmen
DE102019007505A1 (de) * 2019-10-28 2021-04-29 Beiersdorf Ag Zusammensetzung mit probiotischen Bakterien und Licochalcon A
EP3967318A1 (en) * 2020-09-14 2022-03-16 Bionou Research, S.L. Probiotic compositions for the treatment of acne
CN112159781A (zh) * 2020-10-23 2021-01-01 深圳市沁帆科技有限公司 一种植物乳杆菌、微生物菌剂及其应用
CN112553117B (zh) * 2020-12-24 2022-04-29 江南大学 一株能够抑制皮肤角质层增厚的罗伊氏乳杆菌及其应用
US11633348B2 (en) 2021-03-19 2023-04-25 Eligo Bioscience Cosmetic use of engineered postbiotics comprising bacteriocins and/or endolysins
CA3213821A1 (en) * 2021-03-19 2022-09-22 Eligo Bioscience Therapeutic use of engineered postbiotics comprising bacteriocins and/or endolysins
CN113046268B (zh) * 2021-03-24 2023-01-31 华熙生物科技股份有限公司 鼠李糖乳杆菌、调节皮肤微生态的发酵溶胞物、制法及其应用
WO2022233441A1 (en) * 2021-05-07 2022-11-10 Symrise Ag Novel bacterial ferment of lactobacillus species
CN113249269B (zh) * 2021-06-28 2021-09-10 中科嘉亿营养医学(山东)微生态研究院有限公司 具有细胞修复、保湿作用的长双歧杆菌blg-19、应用及产品
CN113637606A (zh) * 2021-08-10 2021-11-12 南京北极光生物科技有限公司 一种后生元和噬菌体复配的微生物组合制剂、制备方法及其应用
EP4134426A1 (en) * 2021-08-13 2023-02-15 Symrise AG Novel bacterial ferment of lactobacillus species
CN114717131B (zh) * 2021-09-07 2023-05-26 青岛蔚蓝生物股份有限公司 一株对皮肤损伤具有保护作用的鼠李糖乳杆菌及其应用
WO2023126644A1 (ru) * 2021-12-28 2023-07-06 Авсистемс Инк. Средство противоинфекционной обработки человека или животных, способ его изготовления и применения
CN115054550A (zh) * 2022-07-05 2022-09-16 中南大学 一种复合面霜及其制备方法和其在护肤方面的应用
CN115386524B (zh) * 2022-10-11 2024-04-09 苏州益优生物科技有限公司 一种乳酸杆菌组合物及其在护肤品中的应用
CN117551590B (zh) * 2024-01-10 2024-04-05 广州集妍化妆品科技有限公司 长双歧杆菌婴儿亚种、微生物菌剂及其应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839281A (en) 1985-04-17 1989-06-13 New England Medical Center Hospitals, Inc. Lactobacillus strains and methods of selection
US5837238A (en) 1996-06-05 1998-11-17 Biogaia Biologics Ab Treatment of diarrhea
ES2221624T3 (es) * 1999-08-26 2005-01-01 Ganeden Biotech, Inc. Uso de aceite de emu como vehiculo para mediaciones antifungicas, antibacterianas y antiviricas.
US7517681B2 (en) 2003-01-29 2009-04-14 Biogaia Ab Selection and use of lactic acid bacteria for reducing dental caries and bacteria causing dental caries
US6872565B2 (en) 2003-01-29 2005-03-29 Biogaia Ab Product containing Lactobacillus reuteri strain ATTC PTA-4965 or PTA-4964 for inhibiting bacteria causing dental caries
WO2006073430A2 (en) * 2004-04-20 2006-07-13 The University Of Chicago Therapeutic delivery system comprising a high molecular weight peg-like compound
AU2005257033B2 (en) 2004-06-23 2011-05-12 L'oreal Method and compositions useful for preventing and/or treating sensitive and/or dry skin
FR2872047B1 (fr) * 2004-06-23 2007-06-15 Oreal Composition pour peaux sensibles associant cation mineral et probiotique(s)
FR2889057B1 (fr) * 2005-08-01 2008-07-18 Oreal Composition cosmetique et/ou dermatologique pour la prevention et/ou le traitement des peaux sensibles ou seches
KR20090085084A (ko) 2006-12-01 2009-08-06 오르가노발란스 게엠베하 병원성 미생물에 대해 피부를 보호하기 위한 조성물, 키트 및 용도
FR2920307B1 (fr) 2007-09-04 2010-06-04 Oreal Utilisation cosmetique de microorganismes.
FR2920304B1 (fr) * 2007-09-04 2010-06-25 Oreal Utilisation cosmetique de lysat bifidobacterium species pour le traitement de la secheresse.
BRPI0916690B1 (pt) * 2008-07-29 2022-04-12 L'oreal Uso de uma quantidade eficaz de pelo menos um microorganismo probiótico, composição coméstica e/ou dermatólogica, método coméstico para tratar e/ou prevenir distúrbios estéticos do couro cabeludo em um indivíduo, processo cosmético para prevenir e/ou tratar uma condição de caspa do couro cabeludo, conjunto cosmético, e, uso cosmético de pelo menos uma quantidade eficaz de pelo menos um primeiro e um segundo agente cosmético ativo
FR2938437B1 (fr) * 2008-11-19 2020-03-27 Société des Produits Nestlé S.A. Utilisation cosmetique de microorganisme pour le traitement des peaux grasses
EP2161329A1 (en) 2008-09-04 2010-03-10 OM Pharma Immunomodulatory extracts from lactobacillus bacteria and methods of manufacturing and use thereof
FR2937547B1 (fr) * 2008-10-28 2012-11-09 Oreal Utilisation d'un lysat de microorganisme pour le traitement des peaux grasses
US20110256179A1 (en) * 2008-11-17 2011-10-20 Essum Ab Pharmaceutical preparation comprising a combination of streptococcus strains and lactobacillus strains
EP2206506A1 (en) * 2008-12-18 2010-07-14 Bracco Imaging S.p.A Probiotic formulations
FR2940908B1 (fr) * 2009-01-12 2012-08-24 Oreal Association cosmetique d'un microorganisme et d'un derive phytosphingosine
JP5792073B2 (ja) * 2009-02-02 2015-10-07 ヴァリオ・リミテッドＶａｌｉｏ Ｌｔｄ ラクトバチルス・ラムノサスの線毛ポリペプチドおよびその生産方法
FR2942719B1 (fr) * 2009-03-04 2011-08-19 Oreal Utilisation de microorganismes probiotiques pour limiter les irritations cutanees
IT1398730B1 (it) 2009-09-08 2013-03-18 Giuliani Spa Ceppo batterico probiotico e suoi usi per via orale e topica
FI20096058A0 (fi) 2009-10-13 2009-10-13 Valio Oy Koostumuksia ja niihin liittyviä menetelmiä ja käyttöjä
FR2953408B1 (fr) * 2009-12-08 2013-02-08 Oreal Microorganismes probiotiques a titre d'actif pour l'eclat du teint de la peau
JP2011132188A (ja) * 2009-12-25 2011-07-07 Kirin Holdings Co Ltd プラスミノーゲン活性化増強作用を有する乳酸菌及びその組成物
CN103037878B (zh) * 2010-06-08 2015-06-24 可尔必思株式会社 脂质代谢改善剂
JP5610472B2 (ja) * 2010-06-21 2014-10-22 学校法人酪農学園 新規乳酸菌及び新規乳酸菌含有組成物
RU2683225C2 (ru) 2011-05-06 2019-03-26 БЕЛАНО Медикал АГ Новые молочнокислые бактерии и содержащие их составы

Also Published As

Publication number Publication date
MX362725B (es) 2019-02-05
US20150079040A1 (en) 2015-03-19
CA2908812A1 (en) 2013-10-17
EP2836223A1 (en) 2015-02-18
BR112014025469B1 (pt) 2022-07-26
AU2013246701B2 (en) 2017-12-07
CA2908812C (en) 2022-04-12
ES2883926T3 (es) 2021-12-09
JP2018115168A (ja) 2018-07-26
EP3888628A1 (en) 2021-10-06
GB201206599D0 (en) 2012-05-30
MX2014012247A (es) 2015-03-05
EP2836223B1 (en) 2021-04-28
CN104582712B (zh) 2020-08-11
HK1201208A1 (en) 2015-08-28
JP6944399B2 (ja) 2021-10-06
AU2013246701A1 (en) 2014-11-06
EP2836223B2 (en) 2024-03-06
US20230088050A1 (en) 2023-03-23
RU2656152C2 (ru) 2018-05-31
JP2015514127A (ja) 2015-05-18
CN104582712A (zh) 2015-04-29
RU2014145534A (ru) 2016-06-10
JP6505594B2 (ja) 2019-04-24
WO2013153358A1 (en) 2013-10-17

Similar Documents

Publication Publication Date Title
BR112014025469A2 (pt) uso de bactérias probióticas no tratamento de infecções bacterianas e regeneração da pele, bem como composições compreendendo cepas das referidas bactérias
BR112017010475A2 (pt) cepas de lactobacillus ou bifidobacterium para manter homeostase
EA201490004A1 (ru) Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей
BR112013019258A8 (pt) Uso de uma formulação probiótica compreendendo uma cepa de bifidobacterium bifidum
MX2019009132A (es) Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
BR112017008344A2 (pt) extrato, uso de um extrato, e, composição cosmética ou dermofarmacêutica.
BR112013020312A2 (pt) composições simbióticas para restauração e reconstituição da microbiota intestinal
MX2015006491A (es) Composiciones bacterianas sinergicas y metodos de produccion y uso de las mismas.
BR112012022755A2 (pt) composição com bactérias probióticas para uso no tratamento de distúrbios imunológicos
PL2364712T3 (pl) Miejscowa kompozycja kosmetyczna lub farmaceutyczna zawierająca probiotyczne szczepy pałeczek bakterii kwasu mlekowego i jej stosowanie
BR112015027536A2 (pt) composição compreendendo mistura de bactérias ácidas lácticas, bem como uso da referida mistura
BR112013028496A2 (pt) cepas bacterianas pertencentes ao gênero bifidobacterium para uso no tratamento de hipercolesterolemia
BR112015026773A2 (pt) cepas bacterianas que têm atividade antimicrobiana e composições de controle biológico que compreendem as mesmas
GB2511993A (en) Prebiotic formulations and methods of use
HUE060892T2 (hu) Probiotikus baktériumtörzsek a szájüreg betegségeinek megelõzésére és kezelésére
EP2796142A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING DEATH CELLS OF LACTOBACILLUS ACIDOPHILUS LB STRAIN FOR THE TREATMENT OR PREVENTION OF ALLERGIC DISEASE
BR112019004288A2 (pt) cepas bacterianas probióticas pertencendo ao gênero bifidobacterium e extratos de células probióticas (pces) das mesmas tendo propriedades imunoestimulantes
BR112017012251A2 (pt) cepas probióticas que têm capacidade absorvente de colesterol, métodos e usos das mesmas
CL2012002902A1 (es) Cepas de bacteriofagos especifica contra bacterias pertenecientes al genero vibrio para la profilaxis y terapia de vibrio anguillarum; y composicion antibacteriana que comprende dicha cepas.
BR112012017300A2 (pt) processo de para preparação de uma biomassa compreendendo plantaricina e usos da mesma no campo médico
UY32650A (es) Medicamento para la administración oral que contiene al menos un esterógeno y/o al menos un gestágeno y al menos una cepa de bacterias probióticas
MX367473B (es) Composiciones de fosfato de calcio sustituido con magnesio amorfo, y sus usos.
WO2011048554A3 (fr) Association d'un lysat de probiotique et d'un derive c-glycoside
BR112012030363A2 (pt) linhagens probióticas para uso na melhoria da resistência transepitelial
WO2014096086A3 (fr) Utilisation de microorganismes probiotiques comme agent favorisant la synthèse de mélanine

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: SKINBIOTIX LIMITED (GB)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: THE UNIVERSITY OF MANCHESTER (GB)

Free format text: ANULADA A PUBLICACAO CODIGO 25.1 NA RPI NO 2494 DE 23/10/2018 POR TER SIDO INDEVIDA.

B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: THE UNIVERSITY OF MANCHESTER (GB)

Free format text: A FIM DE ATENDER AS ALTERACOES DE NOME REQUERIDAS ATRAVES DA PETICAO NO 870180136733, DE 01/10/2018,E NECESSARIO APRESENTAR GUIA DE RECOLHIMENTO, CODIGO 248, RELATIVA A ALTERACAO DE NOME OCORRIDA, AL EM DA GUIA DE CUMPRIMENTO DE EXIGENCIA.

Owner name: THE UNIVERSITY OF MANCHESTER (GB)

Free format text: A FIM DE ATENDER AS ALTERACOES DE NOME REQUERIDAS ATRAVES DA PETICAO NO 870180136733, DE 01/10/2018, E NECESSARIO APRESENTAR GUIA DE RECOLHIMENTO, CODIGO 248, RELATIVA A ALTERACAO DE NOME OCORRIDA, ALEM DA GUIA DE CUMPRIMENTO DE EXIGENCIA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25A Requested transfer of rights approved

Owner name: SKINBIOTIX LIMITED (GB)

B25D Requested change of name of applicant approved

Owner name: SKINBIOTHERAPEUTICS PLC (GB)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/03/2013, OBSERVADAS AS CONDICOES LEGAIS